Literature DB >> 24636073

Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease.

Hiromi Kan1, Yuki Kimura, Hideyuki Hyogo, Takayuki Fukuhara, Hatsue Fujino, Noriaki Naeshiro, Yohji Honda, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Koji Arihiro, Kazuaki Chayama.   

Abstract

AIM: The diagnosis of non-alcoholic fatty liver disease (NAFLD) is based on the histological findings. Further, there may be interobserver differences. Liver to spleen (L/S) ratio on computed tomography (CT) is employed to detect or even quantify the fat content of the liver. The objective of this study was to accurately diagnose fatty liver by evaluating the relationship between L/S ratio and histological findings.
METHODS: Sixty-seven biopsy-proven NAFLD patients were enrolled. L/S ratio on CT was calculated. The area of steatosis in liver specimens was measured by BIOREVO BZ-9000 microscope, and the percentage of steatosis was calculated using Dynamic cell count BZ-H1C software.
RESULTS: Steatotic grade assessed by pathologist was significantly correlated with the percentage of steatosis and L/S ratio. Factors associated with steatosis were L/S ratio, aspartate aminotransferase and Homeostasis Model of Assessment - Insulin Resistance as determined by multivariate analysis. L/S ratios were: S0, 1.16 ± 0.20 (mean ± standard deviation); S1, 0.88 ± 0.28; S2, 0.76 ± 0.20; and S3, 0.40 ± 0.18, respectively. The optimal cut-off value of L/S ratio to exclude steatosis was 1.1, and the area under the receiver-operator curve for the diagnosis of steatosis was 0.886.
CONCLUSION: Our study suggests that while 0% of steatosis showed 1.296 L/S ratio, the cut-off value of L/S ratio would be 1.1 at least to exclude clinically important liver steatosis.
© 2014 The Japan Society of Hepatology.

Entities:  

Keywords:  liver to spleen ratio; non-alcoholic fatty liver disease; non-invasive assessment; steatotic grade

Year:  2014        PMID: 24636073     DOI: 10.1111/hepr.12330

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  9 in total

1.  CT indices for the diagnosis of hepatic steatosis using non-enhanced CT images: development and validation of diagnostic cut-off values in a large cohort with pathological reference standard.

Authors:  Jieun Byun; Seung Soo Lee; Yu Sub Sung; Youngbin Shin; Jessica Yun; Ho Sung Kim; Eun Sil Yu; Sung-Gyu Lee; Moon-Gyu Lee
Journal:  Eur Radiol       Date:  2018-12-19       Impact factor: 5.315

2.  α7-Nicotinic Acetylcholine Receptor Agonist Ameliorates Nicotine Plus High-Fat Diet-Induced Hepatic Steatosis in Male Mice by Inhibiting Oxidative Stress and Stimulating AMPK Signaling.

Authors:  Mohammad Kamrul Hasan; Theodore C Friedman; Carl Sims; Desean L Lee; Jorge Espinoza-Derout; Adaku Ume; Victor Chalfant; Martin L Lee; Indrani Sinha-Hikim; Kabirullah Lutfy; Yanjun Liu; Sushil K Mahata; Amiya P Sinha-Hikim
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

3.  A Model to Predict Significant Macrosteatosis in Hepatic Grafts.

Authors:  Ahmed Swelam; René Adam; Lelde Lauka; Luiza Basilio Rodrigues; Sherif Elgarf; Mylène Sebagh; Nicolas Golse; Antonio Sa Cunha; Daniel Cherqui; Denis Castaing; Marc-Antoine Allard
Journal:  World J Surg       Date:  2020-04       Impact factor: 3.352

4.  Xanthine oxidoreductase activity is correlated with hepatic steatosis.

Authors:  Chisako Yagi; Yoshiki Kusunoki; Taku Tsunoda; Takayo Murase; Takashi Nakamura; Keiko Osugi; Mana Ohigashi; Akiko Morimoto; Akio Miyoshi; Miki Kakutani-Hatayama; Kae Kosaka-Hamamoto; Manabu Kadoya; Kosuke Konishi; Takuhito Shoji; Hidenori Koyama
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

5.  Incidence, predictive factors and severity of methotrexate-related liver injury in rheumatoid arthritis: a longitudinal cohort study.

Authors:  Shunsuke Mori; Nobuyuki Arima; Masahiro Ito; Yukitaka Ueki; Yasuyo Abe; Kiyoshi Aoyagi; Shigetoshi Fujiyama
Journal:  Rheumatol Adv Pract       Date:  2020-06-05

Review 6.  Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis.

Authors:  Rasha AlShaalan; Murad Aljiffry; Said Al-Busafi; Peter Metrakos; Mazen Hassanain
Journal:  Saudi J Gastroenterol       Date:  2015 Mar-Apr       Impact factor: 2.485

Review 7.  Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease.

Authors:  Shujing Lv; Sushan Jiang; Shousheng Liu; Quanjiang Dong; Yongning Xin; Shiying Xuan
Journal:  J Clin Transl Hepatol       Date:  2018-06-22

8.  Improvement of non-alcoholic fatty liver disease after laparoscopic sleeve gastrectomy in Japanese obese patients.

Authors:  Yuichi Endo; Masayuki Ohta; Kazuhiro Tada; Hiroaki Nakanuma; Kunihiro Saga; Takashi Masuda; Teijiro Hirashita; Yukio Iwashita; Yoshinori Ozeki; Takayuki Masaki; Masafumi Inomata
Journal:  Ann Gastroenterol Surg       Date:  2019-01-29

9.  Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma.

Authors:  Norihiko Tokuzen; Koh-ichi Nakashiro; Hiroshi Tanaka; Kazuki Iwamoto; Hiroyuki Hamakawa
Journal:  Oncotarget       Date:  2016-01-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.